## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi
Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck
โ Scribed by George Fountzilas; Christos Tolis; Anna Kalogera-Fountzila; Despina Misailidou; Periklis Tsekeris; Maria Karina; Angelos Nikolaou; Epaminondas Samantas; Thomas Makatsoris; Eleni Athanassiou; Dimosthenis Skarlos; Aristotelis Bamias; Nikolas Zamboglou; Theofanis Economopoulos; Sophia Karanastassi; Nicholas Pavlidis; John Daniilidis
- Book ID
- 111641034
- Publisher
- Springer US
- Year
- 2005
- Tongue
- English
- Weight
- 91 KB
- Volume
- 22
- Category
- Article
- ISSN
- 1357-0560
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract ## BACKGROUND The goal of the current study was to evaluate the efficacy and toxicity of paclitaxel, cisplatin (P), tegafur (T), and leucovorin (L) as a neoadjuvant chemotherapy (CT) for patients with advanced, unresectable squamous cell carcinoma of the head and neck. ## METHODS Fro